PLUSMUV®
ROFLUMILAST 0.50 mg

Film-coated tablets

Argentine Industry - Rx only

Composition:

Each film-coated tablet contains roflumilast 0.50 mg, lactose monohydrate, povidone K-90, corn starch, magnesium stearate, sunset yellow aluminium lake, Opadry II white.

Therapeutic Action:

Non-steroid anti-inflammatory agent; phosphodiesterase 4 (PDE4) inhibitor; treatment for airway obstructive diseases.

Indications:

PLUSMUV® film-coated tablets for oral administration is indicated to reduce the risk of COPD exacerbations in patients with severe COPD (VEMS post-dilator less than 50 % of the normal) associated with chronic bronchitis in adults with a history of frequent exacerbations, and as additional therapy with bronchodilators. 

Storage:

Keep at room temperature (below 30 °C) protected from the light, in its marketed packing.

Marketed presentations:

Cartons containing 10, 30, and 90 film-coated tablets
Cartons containing 500 film-coated tablets for use in hospitals

Medicinal speciality authorised by the Ministry of Health
Certificate No. 57399

Laboratorio DOSA S.A. 
Girardot 1369, (C1427AKC) City of Buenos Aires, Argentina.
Pharmaceutical Director: María C. Terzo, Pharmacist.